- Home
- BCTX
as 05-08-2025 4:00pm EST
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
| Founded: | 2014 | Country: | Canada |
| Employees: | N/A | City: | WEST VANCOUVER |
| Market Cap: | 16.1M | IPO Year: | N/A |
| Target Price: | $32.00 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $9.82 | Next Earning Date: | 06-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BriaCell Therapeutics Corp. News
BCTX Breaking Stock News: Dive into BCTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
GlobeNewswire
10 days ago
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
MT Newswires
11 days ago
BriaCell Therapeutics Lower, Says Presenting Positive Phase 2 Data at AACR
GlobeNewswire
11 days ago
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
MT Newswires
14 days ago
BriaCell Therapeutics to Raise $13.8 Million in Public Offering; Shares Fall
MT Newswires
14 days ago
BriaCell Therapeutics Down 17% In US Premarket As Prices US$13.8 Million Public Offering
GlobeNewswire
14 days ago
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
MT Newswires
15 days ago
Update: BriaCell Jumps More Than 30% As Reports Complete Lung Metastasis Resolution in Patient
Compare BCTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCTX BriaCell Therapeutics Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.